DENDREON PHARMACEUTICALS, LLC

Lobbying client · California · filed 2025 to 2026

$627,184 Reported spend

14 Filings counted

1 Outside firm hired

2 Bills named

Spend is reported income plus in-house expenses across 14 filings. The LDA keeps a separate client record for every registrant that files for a client, so this page adds up 2 records, one per registrant listed below. Records are combined when the client name matches once case, punctuation and endings such as Inc. or LLC are set aside; for a city, county or port the state has to match as well. These filings have also been reported as DENDREON PHARMACEUTICALS LLC.

Who filed for this client 2

DENDREON PHARMACEUTICALS, LLC $417,184 In-house, the client's own filings · 7 filings
THE MCMANUS GROUP $210,000 Outside firm · 7 filings

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

Bills named in these filings 2

H.R. 1300
PSA Screening for HIM Act

2 filings
S. 297
PSA Screening for HIM Act

2 filings

Reported by year 2 years

2026 $268,950 6 filings
2025 $358,234 8 filings

Issues lobbied 4

Veterans 9
Medicare/Medicaid 8
Medical/Disease Research/Clinical Labs 3
Health Issues 2

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 2

HOUSE OF REPRESENTATIVES 14
SENATE 11

Recent filings 14 total

Q3 report

DENDREON PHARMACEUTICALS, LLC

3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $59,650 expenses · posted Nov 4, 2026

View → Q3 report

THE MCMANUS GROUP

3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $30,000 income · posted Oct 20, 2026

View → Q2 report

DENDREON PHARMACEUTICALS, LLC

2nd Quarter 2026 (Apr 1 - June 30) · House · $59,650 expenses · posted Sep 9, 2026

View → Q2 report

THE MCMANUS GROUP

2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $30,000 income · posted Jul 20, 2026

View → Q1 report

DENDREON PHARMACEUTICALS, LLC

1st Quarter 2026 (Jan 1 - Mar 31) · House · $59,650 expenses · posted May 26, 2026

View → Q1 report

THE MCMANUS GROUP

1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $30,000 income · posted Apr 20, 2026

View → Q4 report

DENDREON PHARMACEUTICALS, LLC

4th Quarter 2025 (Oct 1 - Dec 31) · House · $59,650 expenses · posted Feb 25, 2026

View → Q4 report

THE MCMANUS GROUP

4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $30,000 income · posted Jan 20, 2026

View → Q3 report

DENDREON PHARMACEUTICALS, LLC

3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $59,650 expenses · posted Dec 2, 2025

View → Q3 report

THE MCMANUS GROUP

3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $30,000 income · posted Oct 20, 2025

View → Q2 report

DENDREON PHARMACEUTICALS, LLC

2nd Quarter 2025 (Apr 1 - June 30) · House · Senate · $58,787 expenses · posted Aug 19, 2025

View → Q2 report

THE MCMANUS GROUP

2nd Quarter 2025 (Apr 1 - June 30) · House · Senate · $30,000 income · posted Jul 21, 2025

View → Q1 report

DENDREON PHARMACEUTICALS, LLC

1st Quarter 2025 (Jan 1 - Mar 31) · House · Senate · $60,147 expenses · posted May 6, 2025

View → Q1 report

THE MCMANUS GROUP

1st Quarter 2025 (Jan 1 - Mar 31) · House · Senate · $30,000 income · posted Apr 21, 2025

View →

Keep going

Filings through November 4, 2026, the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.